Agilent Technologies (A) said Thursday its PD-L1 IHC 22C3 pharmDx assay has received European In Vitro Diagnostic Regulation certification for use as a companion diagnostic to identify gastric or gastroesophageal junction adenocarcinoma patients who may be treated with Merck's (MRK) Keytruda.
The company said PD-L1 IHC 22C3 pharmDx assay is now IVDR certified as an aid in seven cancer indications for treatment with Keytruda.
Agilent said it developed the test in partnership with Merck, which developed Keytruda.
Price: 102.37, Change: -0.34, Percent Change: -0.33
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.